Milestone Pharmaceuticals

MIST

ATLANTA, GA – – (Globe Newswire – December 28, 2023) – – Holzer & Holzer, LLC is investigating whether Milestone Pharmaceuticals Inc. (“Milestone Pharmaceuticals” or the “Company”) (NASDAQ: MIST) complied with federal securities laws.  On December 26, 2023, the Company disclosed it had received a Refusal to File (“RTF”) letter from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application (“NDA”) for Etripamil. During preliminary review of the NDA, the FDA determined it “was not sufficiently complete to permit substantive review” and “requested clarification about the time of data recorded for adverse events in Phase 3 clinical trials.” Following this news, the price of the Company’s stock dropped.

If you purchased Milestone Pharmaceuticals stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/milestone-pharmaceuticals/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share